Barclays analyst Manav Patnaik maintains Gartner (NYSE:IT) with a Equal-Weight and raises the price target from $330 to $350.
BriaCell Announces End Of Phase II Meeting With FDA For Bria-IMT Combination In Advanced Metastatic Breast Cancer; FDA Has Agreed On Primary Endpoint
BriaCell has received agreement and positive feedback from its End of Phase II meeting with the FDA for lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic breast
